DK2041576T3 - Differentiel cytokinekspression i humane cancere - Google Patents

Differentiel cytokinekspression i humane cancere

Info

Publication number
DK2041576T3
DK2041576T3 DK07764767.5T DK07764767T DK2041576T3 DK 2041576 T3 DK2041576 T3 DK 2041576T3 DK 07764767 T DK07764767 T DK 07764767T DK 2041576 T3 DK2041576 T3 DK 2041576T3
Authority
DK
Denmark
Prior art keywords
human cancers
cytokine expression
differential cytokine
differential
expression
Prior art date
Application number
DK07764767.5T
Other languages
English (en)
Inventor
Christian Gieffers
Oliver Hill
Giorgio Stassi
Matilde Todaro
Meinolf Thiemann
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Application granted granted Critical
Publication of DK2041576T3 publication Critical patent/DK2041576T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK07764767.5T 2006-06-21 2007-06-21 Differentiel cytokinekspression i humane cancere DK2041576T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (1)

Publication Number Publication Date
DK2041576T3 true DK2041576T3 (da) 2011-12-05

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07764767.5T DK2041576T3 (da) 2006-06-21 2007-06-21 Differentiel cytokinekspression i humane cancere

Country Status (12)

Country Link
US (1) US20090324616A1 (da)
EP (1) EP2041576B1 (da)
JP (1) JP2010514409A (da)
CN (1) CN101529253A (da)
AT (1) ATE520032T1 (da)
AU (1) AU2007263265A1 (da)
BR (1) BRPI0713484A2 (da)
CA (1) CA2656379A1 (da)
DK (1) DK2041576T3 (da)
ES (1) ES2371287T3 (da)
RU (1) RU2009101783A (da)
WO (1) WO2007147600A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007228943B2 (en) * 2006-03-22 2012-03-22 Apogenix Gmbh Antibody specific for human IL-4 for the treament of cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
CA2877989C (en) * 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
WO2016065330A1 (en) * 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
JP2020513574A (ja) * 2016-11-24 2020-05-14 ヒュベット バイオ, インコーポレイテッドHuvet Bio, Inc. 疾患の診断用組成物
CA3071661A1 (en) * 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1995007301A1 (en) 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US6159937A (en) * 1994-07-05 2000-12-12 Steeno Research Group A/S Immunomodulators
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6905684B1 (en) * 1997-11-10 2005-06-14 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung diseases
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US20020076409A1 (en) * 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
EP1578912A4 (en) * 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP2008520684A (ja) * 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
AU2007228943B2 (en) * 2006-03-22 2012-03-22 Apogenix Gmbh Antibody specific for human IL-4 for the treament of cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy

Also Published As

Publication number Publication date
EP2041576B1 (en) 2011-08-10
EP2041576A2 (en) 2009-04-01
CA2656379A1 (en) 2007-12-27
ATE520032T1 (de) 2011-08-15
AU2007263265A1 (en) 2007-12-27
US20090324616A1 (en) 2009-12-31
CN101529253A (zh) 2009-09-09
BRPI0713484A2 (pt) 2012-11-06
WO2007147600A2 (en) 2007-12-27
JP2010514409A (ja) 2010-05-06
WO2007147600A3 (en) 2008-04-10
RU2009101783A (ru) 2010-07-27
ES2371287T3 (es) 2011-12-29

Similar Documents

Publication Publication Date Title
ATE520032T1 (de) Differentielle cytokinexpression bei einer menschlichen krebserkrankung
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
EA201591754A1 (ru) Человеческие антитела к na1.7
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
ZA201604468B (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
CY1118714T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
ATE448232T1 (de) Substituierte heterozyklen
WO2012145535A3 (en) Animal model of human cancer and methods of use
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2008053484A3 (en) Preparation of heavy metal-containing nano-liposomes and their uses in medical therapy
MY179250A (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
ATE511551T1 (de) Aus lebendigen tumorzellen ausgewählte aptamere und deren verwendung
MX356814B (es) Métodos y composiciones para neuroprotección.
MX2007006355A (es) Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico.
WO2009091230A3 (ko) 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
CO6612209A2 (es) Terapia antia-agiogénesis para el tratamiento de cáncer de mama previamente tratado
EA201500765A1 (ru) Способы лечения сердечно-сосудистых заболеваний
PH12015502516A1 (en) Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment